



153/123

PATENT
Our Docket: P31 8929


CR189
11/13/92
P31-13-92

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)
Geoffrey M. Wahl)
Stephen V. O'Gorman)
Serial No.: 07/666,252)
Filed: March 8, 1991)
For: FLP-MEDIATED GENE)
MODIFICATION IN MAMMALIAN)
CELLS, AND COMPOSITIONS)
AND CELLS USEFUL THEREFOR)

Group Art Unit: 1814

Examiner: C. Low



I hereby certify that this correspondence is being deposited
with the United States Postal Service as first class mail in an
envelope addressed to: Commissioner of Patents and Trade
mark, Washington, D. C. 20231, on 1/14/92

Box SEQUENCE
HON. COMMISSIONER
OF PATENTS & TRADEMARKS
WASHINGTON, D.C. 20231

BY Stephen E. Reiter Reg. No. 31,192
1/14/92
Date of Signature

COMMUNICATION

Dear Sir:

Responsive to the NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR
AMINO ACID SEQUENCE DISCLOSURES, mailed September 30, 1991, the
following are provided:

- (1) a copy of the NOTICE,
- (2) a copy of the sequence information presented at
pages 29-34 of the specification in computer
readable form,
- (3) replacement pages 29-34 of the specification, and
- (4) a statement under 37 CFR §1.821(g).

Respectfully submitted,

By: Stephen E. Reiter
Stephen E. Reiter
Reg. No. 31,192
Telephone: (619) 535-9001
Facsimile: (619) 535-8949

Pretty, Schroeder
Brueggemann & Clark
444 South Flower Street, Suite 2000
Los Angeles, California 90071



PATENT

Our Docket: P31 8929

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:
Geoffrey M. Wahl
Stephen V. O'Gorman


Serial No.: 07/666,252

Filed: March 8, 1991

For: FLP-MEDIATED GENE
MODIFICATION IN MAMMALIAN)
CELLS, AND COMPOSITIONS)
AND CELLS USEFUL THEREFOR)

Group Art Unit: 1814

Examiner: C. Low



I hereby certify that this correspondence being deposited
with the United States Postal Service as first class mail in an
envelope addressed to: Commissioner of Patents and Trade
marks, Washington, D. C. 20231, on 1/14/92

BY

Stephen E. Reiter Reg. No. 31,192

1/14/92
Date of Signature

Box SEQUENCE
HON. COMMISSIONER
OF PATENTS & TRADEMARKS
WASHINGTON, D.C. 20231

STATEMENT UNDER 37 CFR §1.821(g)

Sir:

I hereby state that the submission, filed in accordance
with 37 CFR §1.821(g), herein, does not include new matter.

Respectfully submitted,

By:

Stephen E. Reiter

Reg. No. 31,192

Telephone: (619) 535-9001

Facsimile: (619) 535-8949

Pretty, Schroeder
Brueggemann & Clark
444 South Flower Street
Suite 2000
Los Angeles, California 90071

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR § 1.821(a)(1) and (a)(2). However, this application fails to comply with one or more of the requirements of 37 CFR §§ 1.821 through 1.825 as follows:

- ☐ 1. This application clearly fails to comply with the collective requirements of §§ 1.821 through 1.825. Applicant's attention is directed to these regulations, a copy of which is attached.
- ☐ 2. This application does not conform exclusively to the requirements of §§ 1.821 through 1.825. The non-conforming material should be deleted. § 1.821(b).
- ☐ 3. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing." § 1.821(c).
- ☒ 4. This application does contain, as a separate part of the disclosure on paper copy, a "Sequence Listing." However, the "Sequence Listing" does not comply with the requirements of §§ 1.821 through 1.825 as follows:
- ☐ a. The sequence data does not comply with the symbol and format requirements of paragraphs (b) through (p) of § 1.822. Specifically: _____
- ☐ b. The "Sequence Listing" does not comply with the location and page requirements of paragraph (a) of § 1.823.
- ☐ c. The "Sequence Listing" does not comply with the information requirements of paragraph (b) of § 1.823. Specifically: _____
- ☒ d. Other: there is no listing for the sequences at pages 11 and 17
- ☐ 5. The description and/or claims of the patent application mention a sequence that is set forth in the "Sequence Listing" but reference is not properly made to the sequence by use of a sequence identifier as required by § 1.821(d).
- ☐ 6. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by § 1.821(e).
- ☒ 7. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the computer readable form does not comply with the requirements of § 1.824. Specifically: See item 4 d. above with regard to the sequences at pages 11 and 17
- ☒ 8. A statement that the content of the paper and computer readable copies are the same has not been submitted as required by § 1.821(f).
- ☐ 9. The amendment to or replacement of the paper and/or computer readable copies of the "Sequence Listing" does not comply with the requirements of § 1.825(a) through (c).
- ☐ 10. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable. Applicant must provide a substitute copy of the data in computer readable form accompanied by a statement that the substitute data is identical to that originally filed. § 1.825(d). Specifically: _____
- ☐ 11. Other: _____

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE ABOVE REQUIREMENTS. Failure to comply with the above requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR § 1.136. Direct the response to, and any questions about, this notice to the undersigned. A copy of this notice MUST be returned with your response.

☐ _____
For: Manager, Application Processing Division
(703) 308-1202 or 308- _____

☒ Christopher Low
Examining Group 1814
(703) 308-0196